InstalabLoading...
InstalabLoading...
Your immune system relies on specialized cells called plasmablasts to produce antibodies during infections, vaccinations, and immune activation. This test counts a specific slice of those cells in your blood, giving you a window into how actively your body is generating new antibody-producing machinery.
This is an exploratory research-grade marker, not a routine clinical test. It is most often used by specialists evaluating antibody-deficiency disorders, certain autoimmune conditions, and blood cancers, but it can also reveal patterns of immune activation that standard immunoglobulin panels miss entirely.
Lab analysts use a technique called flow cytometry to sort your B cells (a class of immune cell that makes antibodies) by the proteins on their surface. CD19 (a tag found on all B cells) identifies the B-cell population. CD38 (a surface protein that turns on when B cells become active antibody factories) marks cells that are heavily engaged. IgM (the first-response antibody class) is absent on cells that have switched to making more advanced antibodies like IgG.
Cells that are CD38-positive and IgM-negative within the CD19 group are mostly plasmablasts and plasma-cell-like cells: late-stage, class-switched, antibody-secreting B cells. A higher percentage means more of your B cells are in active antibody-production mode. A lower percentage can mean your body is making fewer of these mature responders.
Plasmablasts are the workhorses of a real-time antibody response. When you fight off a virus, get a vaccine, or develop an autoimmune flare, this population shifts. Tracking it gives a more granular view of immune activity than measuring total antibody levels in your blood, because plasmablasts can rise or fall well before total immunoglobulins do.
In a study of antibody-deficiency patients, the plasmablast gate (CD27-high CD38-positive within CD19) was significantly reduced compared to healthy controls, falling to roughly 0.13% of immune cells versus about 0.52% in controls. This means an unusually low result can flag a body that is struggling to mount a full antibody response, sometimes years before it shows up as low IgG on a standard panel.
Active autoimmune disease often shows up as expanded plasmablast or related CD38-positive B-cell populations, because the immune system is producing self-reactive antibodies. The pattern is consistent across several conditions, though the exact subset definitions vary.
In primary Sjögren's syndrome, where the immune system attacks tear and saliva glands, patients show expanded CD19-positive plasma cell and plasmablast populations that correlate with higher serum IgG levels and gland inflammation. In systemic sclerosis (a connective tissue disease that causes scarring), CD38-high plasmablasts and plasma cells are elevated, and this expansion has been linked to pulmonary fibrosis (lung scarring) and more severe disease forms.
In atopic dermatitis (a chronic skin inflammation condition), patients show roughly 3.2 to 3.5% plasmablast-type cells within their B-cell pool, compared to about 2% in psoriasis patients and healthy controls. This reflects the IgE-skewed humoral activity that drives chronic skin inflammation.
This is where the test does some of its most useful work. Some people have low total antibody levels but no clear diagnosis; others have a borderline diagnosis of common variable immunodeficiency (CVID, an inherited or acquired deficiency in antibody production). Looking at the cellular machinery, not just the antibody output, can help sort these out.
Patients with diverse antibody-production defects had significantly fewer CD38-positive plasmablasts than healthy controls. The cells that make antibodies are themselves missing or impaired, which is information you cannot get from measuring IgG, IgA, or IgM concentrations alone. If you have a history of recurrent infections, low immunoglobulins, or a suspected immunodeficiency, this marker can refine the picture.
In chronic lymphocytic leukemia (CLL, a slow-growing blood cancer of B cells), the percentage of CD38-positive leukemic cells helps stratify risk. A cutoff of 30% or higher CD38-positive cells within the leukemic B-cell population is associated with unmutated immune-gene status, poorer chemotherapy response, and shorter survival. CD38 measurement contributes to multivariable prognostic scores in CLL alongside age, stage, and genetic markers.
In double or triple-hit lymphomas (aggressive B-cell cancers with multiple genetic rearrangements), bright CD38 expression on flow cytometry has about 50% sensitivity and 90% specificity for detecting these high-risk subtypes. Very bright CD38 is highly specific, with a positive predictive value of 100% but lower sensitivity of about 30%.
This is not a marker where higher is straightforwardly bad or lower is straightforwardly good. A high percentage might reflect a strong, healthy response to a vaccine or an infection, or it might reflect autoimmune over-activation. A low percentage might indicate a quiet, well-regulated immune system, or a deficiency in your body's ability to make antibodies. The number is a phenotype indicator, not a verdict. Interpretation depends on context: your symptoms, other lab results, recent infections or vaccinations, and the disease being investigated.
There are no universally agreed-upon reference ranges for this specific gate. Cutpoints reported in the published literature come from individual research studies, each with its own gating strategy, patient population, and assay setup. The values below come from a small study using flow cytometry with variable lymphocyte receptor reagents. They are illustrative orientation only, not a target. Your lab will likely report different numbers and may use different gate definitions entirely.
| Group | Approximate plasmablast % of immune cells | What it suggests |
|---|---|---|
| Healthy controls | Around 0.5% | Typical baseline range for active antibody production |
| Antibody-deficiency patients | Around 0.13% | Reduced output, consistent with impaired terminal B-cell differentiation |
| Atopic dermatitis | Around 3.2 to 3.5% (within B-cell pool) | Expanded class-switched antibody production, often IgE-skewed |
Source: Nair et al., 2024 (controls and antibody-deficiency); Czarnowicki et al., 2015 (atopic dermatitis). Compare your results within the same lab over time for the most meaningful trend, since assay differences across labs can shift absolute values substantially.
This marker is dynamic. It rises and falls with infections, vaccinations, autoimmune flares, and treatment changes. A single snapshot can mislead you in either direction. Tracking the trend over time is far more valuable than any one number.
Get a baseline when you are healthy and not recently vaccinated or sick. Retest in 3 to 6 months if you are starting a new immunomodulating treatment, recovering from a serious infection, or investigating an autoimmune condition. After that, at least annually if you are managing a chronic immune condition, or every 6 months if you are on a B-cell-depleting therapy. The trajectory tells you whether your immune activity is stable, escalating, or recovering.
This marker is rarely interpreted in isolation. If your result is unexpectedly high or low, the next step is usually a fuller B-cell phenotyping panel that includes CD27, IgD, and CD24, which together distinguish naive, transitional, memory, and plasmablast subsets. Pair this with serum immunoglobulin levels (IgG, IgA, IgM) and, if autoimmunity is suspected, autoantibody panels and inflammation markers.
If you have low plasmablasts plus low total IgG and a history of recurrent infections, an immunology consultation is warranted to evaluate for primary antibody deficiency. If you have high plasmablasts plus elevated autoantibodies or inflammation markers, a rheumatologist can help work up active autoimmune disease. If you have abnormal results with no symptoms, retest in 4 to 8 weeks to confirm before pursuing further investigation.
Evidence-backed interventions that affect your CD38+ IgM- % of CD19+ B cells level
CD38+ IgM- % of CD19+ B cells is best interpreted alongside these tests.